公开(公告)号：US20020161183A1

公开(公告)日：2002-10-31

申请号：US09846348

申请日：2001-04-30

Inventor： George Jackowski ,  Brad Thatcher ,  John Marshall ,  Jason Yantha ,  Tammy Vrees

IPC: A61K038/00 ,  C07K005/00 ,  C07K007/00 ,  C07K016/00 ,  C07K017/00 ,  A61K038/04

CPC classification number: G01N33/6893 ,  G01N2800/042 ,  Y10T436/24 ,  Y10T436/25

Abstract: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Abstract translation: 本发明涉及使用组合的准备步骤与质谱法和飞行时间检测程序的组合，以使特定样品中可验证的生物聚合物的多样性最大化。 然后，在这样一个样本中验证的生物聚合物队列参照其证明至少一种特定疾病状态的能力; 从而使得诊断者能够获得表征所述至少一种疾病状态的存在或不存在与识别所述生物聚合物的存在和/或不存在的能力。

公开(公告)号：US20020161178A1

公开(公告)日：2002-10-31

申请号：US09976736

申请日：2001-10-09

Applicant: Amgen Inc.

Inventor： Michael Brian Bass ,  John Kevin Sullivan ,  Lars Eyde Theill ,  Daguang Wang

IPC: C07H021/02 ,  C07H021/04 ,  A61K031/70 ,  A01N043/04 ,  C12P019/34 ,  C12N007/00 ,  C12N007/01 ,  C12N007/02 ,  C07K002/00 ,  C07K004/00 ,  C07K005/00 ,  C07K007/00 ,  C07K014/00 ,  C07K016/00 ,  C07K017/00 ,  A61K038/00 ,  C12N015/00 ,  C12N015/09 ,  C12N015/63 ,  C12N015/70 ,  C12N015/74 ,  C12N005/06 ,  C12N005/16 ,  G01N033/53

CPC classification number: C07K14/47 ,  C07K14/475

Abstract: Disclosed are nucleic acid molecules encoding novel DKR polypeptides. Also disclosed are methods of preparing the nucleic acid molecules and polypeptides, and methods of using these molecules.

Abstract translation: 公开了编码新型DKR多肽的核酸分子。 还公开了制备核酸分子和多肽的方法，以及使用这些分子的方法。

公开(公告)号：US20020155562A1

公开(公告)日：2002-10-24

申请号：US09954433

申请日：2001-09-17

Applicant: Leopold Flohe

Inventor： Leopold Flohe ,  Kerstin Koenig ,  Ulrich Menge

IPC: C07H021/04 ,  C12N009/00 ,  C12N009/96 ,  C12N001/00 ,  C12N001/10 ,  C07K002/00 ,  C07K004/00 ,  C07K005/00 ,  C07K007/00 ,  C07K014/00 ,  C07K016/00 ,  C07K017/00 ,  A61K038/00 ,  C07K001/00

CPC classification number: C12N9/93 ,  A61K38/00 ,  Y10S435/947

Abstract: The present invention describes an enzyme showing glutathionylspermidine synthetase-activity and being distinct from known enzymes with similar activities in several physicochemical parameters, a novel process to isolate said enzyme from Crithidia fasciculata, tools for the production thereof in genetically transformed organisms, and its use as a molecular target for the discovery of trypanocidal drugs.

Abstract translation: 本发明描述了一种酶，其显示出谷胱甘肽精氨酸合成酶活性，并且与几种物理化学参数中具有相似活性的已知酶不同，一种将所述酶与Crithidia fasciculata分离的新方法，用于在遗传转化的生物中生产的工具及其用途 发现杀真菌药物的分子靶点。

公开(公告)号：US20020151678A1

公开(公告)日：2002-10-17

申请号：US09911838

申请日：2001-07-24

Applicant: Board of Regents, The University of Texas System.

Inventor： Ralph B. Arlinghaus

IPC: C12Q001/70 ,  C07H021/04 ,  A61K039/21 ,  C07K002/00 ,  C07K004/00 ,  C07K005/00 ,  C07K007/00 ,  C07K014/00 ,  C07K016/00 ,  C07K017/00 ,  A61K038/00 ,  A61K038/04 ,  C07K001/00

CPC classification number: C07K14/005 ,  A61K39/00 ,  C12N2740/16122 ,  G01N33/505 ,  G01N2333/16

Abstract: An active peptide consisting essentially of 7 to about 30 residence and having a sequence that corresponds to a conserved domain of an HIV protein is disclosed, as is a multimer containing that peptide, an aqueous composition containing the multimer and methods of using and making the same. The aqueous composition containing an immunologically effective amount of an active peptide multimer, when introduced into an immunocompetent host animal in an immunologically effective amount, is capable of inducing cellular immunity against the native HIV protein to which the active peptide of the multimer corresponds in sequence, but is not capable of inducing production of antibodies that immunoreact with that native HIV protein.

公开(公告)号：US20020147325A1

公开(公告)日：2002-10-10

申请号：US09223490

申请日：1998-12-30

Inventor： PAUL J. GODOWSKI ,  MELANIE R. MARK ,  DAVID T. SCADDEN ,  KEVIN P. BAKER ,  WILL F. BARON

IPC: C07H021/04 ,  C12P021/06 ,  C12N015/00 ,  C12N015/09 ,  C12N015/63 ,  C12N015/70 ,  C12N015/74 ,  C07K005/00 ,  C07K007/00 ,  C07K016/00 ,  C07K017/00 ,  A61K038/00 ,  C12N005/00 ,  C12N005/02 ,  C07K001/00 ,  C07K014/00 ,  C12P021/08

CPC classification number: C07K16/28 ,  A61K38/00 ,  C07K14/705 ,  C07K14/71 ,  C07K14/715 ,  C12N9/12 ,  C12Q1/485 ,  G01N33/54306 ,  G01N33/566 ,  G01N33/573 ,  G01N2333/705 ,  G01N2333/912 ,  G01N2333/9121 ,  G01N2500/00 ,  Y10S435/975

Abstract: The protein tyrosine kinase receptors, designated Rse and HPTK6, have been purified from human and/or murine cell tissues. Rse and HPTK6 have been cloned from a cDNA library of a human liver carcinoma cell line (i.e., Hep 3B) using PCR amplification. Provided herein are nucleic acid sequences encoding Rse and HPTK6 useful as diagnostics and in the recombinant preparation of Rse and HPTK6. Rse and HPTK6 are used in the preparation and purification of antibodies thereto and in diagnostic assays.

Abstract translation: 已经从人和/或鼠细胞组织中纯化称为Rse和HPTK6的蛋白酪氨酸激酶受体。 已经使用PCR扩增从人肝癌细胞系（即Hep 3B）的cDNA文库克隆了Rse和HPTK6。 本文提供了编码Rse和HPTK6的核酸序列，其可用作诊断和Rse和HPTK6的重组制备。 Rse和HPTK6用于制备和纯化其抗体和诊断测定。

公开(公告)号：US20020146819A1

公开(公告)日：2002-10-10

申请号：US09852391

申请日：2001-05-09

Inventor： John E. Sims ,  Stewart D. Lyman ,  Hilary J. McKenna ,  Allison P. Armstrong

IPC: C12P021/08 ,  C07K017/00 ,  C07K016/00 ,  C07K007/00 ,  C07K005/00 ,  C12N015/74 ,  C12N015/70 ,  C12N015/63 ,  C12N015/09 ,  A01N037/18 ,  A61K038/00 ,  C07H021/04 ,  C12P021/06 ,  C12N015/00

CPC classification number: C07K14/52 ,  A61K38/00 ,  C07K14/475 ,  C07K14/5418 ,  C07K16/24 ,  C12N5/0636

Abstract: The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.

Abstract translation: 本发明涉及纯化和分离的新型TSLP多肽，编码此类多肽的核酸，用于产生重组形式的此类多肽的方法，针对这些多肽产生的抗体，衍生自这些多肽的片段化肽以及上述用途。

公开(公告)号：US20020142946A1

公开(公告)日：2002-10-03

申请号：US09800856

申请日：2001-03-05

Inventor： Yat Sun Or ,  Tsvetelina Lazarova

IPC: A61K038/00 ,  A61K038/12 ,  C07K005/00 ,  C07K007/00 ,  C07K016/00 ,  C07K017/00

CPC classification number: C07K7/645 ,  A61K38/00

Abstract: The present invention relates to novel semisynthetic cyclosporin analogs of Formula (I): 1 X is absent, nullC1-C6 alkyl-, or nullC3-C6 cycloalkyl- Y is selected from the group consisting of: (i) C(O)nullOnullR1, where R1 is hydrogen, C1-C6 alkyl, optionally substituted with halogen, heterocyclic, aryl, C1-C6 alkoxy, C1-C6 alkylthio, halogen-substituted C1-C6 alkoxy, or halogen-substituted C1-C6 alkylthio; (ii) C(O)nullSnullR1, where R1 is as previously defined; (iii) C(O)nullOCH2nullOC(O)R2, where R2 is C1-C6 alkyl, optionally substituted with halogen, C1-C6 alkoxy; C1-C6 alkylthio, heterocyclic or aryl; (iv) C(S)nullOnullR1, where R1 is as previously defined, and (v) C(S)nullSnullR1, where R1 is as previously defined; B is -nullAbu-, -Val-, -Thr- or -Nva-; and U is -(D)Ala-, -(D)Ser-, nullnullOnull(2-hydroxyethyl)(D)Sernull-, nullnullO-acyl(D)Sernull- or nullnullOnull(2-acyloxyethyl)(D)Sernull-.

Abstract translation: 本发明涉及式（I）的新型半合成环孢菌素类似物：X不存在，-C 1 -C 6烷基 - 或-C 3 -C 6环烷基-Y选自：（i）C（O） - O-R 1，其中R 1是氢，任选被卤素，杂环，芳基，C 1 -C 6烷氧基，C 1 -C 6烷硫基，卤素取代的C 1 -C 6烷氧基或卤素取代的C 1 -C 6烷硫基取代的C 1 -C 6烷基; （ⅱ）C（O）-S-R 1，其中R 1如前所定义; （ⅲ）C（O）-OCH 2 -O（O）R 2，其中R 2为任选被卤素，C 1 -C 6烷氧基取代的C 1 -C 6烷基; C 1 -C 6烷硫基，杂环或芳基; （iv）C（S）-O-R 1，其中R 1如前所定义，和（ⅴ）C（S）-S-R 1，其中R 1如前所定义; B是-alphaAbu-，-Val-，-Thr-或-Nva-; 并且U是 - （D）Ala-， - （D）Ser-， - [O-（2-羟乙基）（D）Ser] - ， - [O-酰基（D）Ser] - 或 - 2-酰氧基乙基）（D）Ser] - 。

公开(公告)号：US20020132996A1

公开(公告)日：2002-09-19

申请号：US09955807

申请日：2001-09-19

Applicant: ZymoGenetics, Inc.

Inventor： Si Lok ,  Paul O. Sheppard ,  Wayne Kindsvogel ,  Susan J. Bort

IPC: C07H021/02 ,  C07H021/04 ,  C07K005/00 ,  C07K007/00 ,  C07K016/00 ,  C07K017/00 ,  A61K038/00 ,  C12P021/08

CPC classification number: C07K14/52 ,  A61K38/00 ,  C12N2799/026

Abstract: Secretory Protein-48 (Zsig48), polypeptides, polynucleotides encoding said polypeptides, antibodies which specifically bind to Zsig48 and anti-idiotypic antibodies. Zsig48 polypeptides cause leukocytes to proliferate and thus can be used to elevate leukocytes in cancer treatments and in immunosuppressed patients.

Abstract translation: 分泌蛋白-48（Zsig48），多肽，编码所述多肽的多核苷酸，特异性结合Zsig48和抗独特型抗体的抗体。 Zsig48多肽导致白细胞增殖，因此可用于在癌症治疗和免疫抑制患者中提高白细胞。

公开(公告)号：US20020132974A1

公开(公告)日：2002-09-19

申请号：US08750187

申请日：1997-03-10

Inventor： NEVILLE BODEN ,  AMAILIA AGGELI ,  THOMAS CHARLES BUCKLAND MCLEISH

IPC: A61K038/00 ,  C07K005/00 ,  C07K007/00 ,  C07K016/00 ,  C07K017/00

CPC classification number: C12N9/2462 ,  C07K14/001 ,  C07K14/705

Abstract: The invention relates to novel peptides which are able to form gels in solutions, which gels have favourable properties in that, under specified conditions, they can be made to switch from a gel state to either a fluid state or a stiffer gel state

Abstract translation: 本发明涉及能够在溶液中形成凝胶的新型肽，该凝胶具有有利的性质，因为在特定条件下，它们可以从凝胶状态转变为流体状态或更硬的凝胶状态

公开(公告)号：US20020132763A1

公开(公告)日：2002-09-19

申请号：US09985997

申请日：2001-11-07

Inventor： Salvaraj Naicker ,  Randall W. Yatscoff ,  Robert T. Foster

IPC: A61K038/00 ,  C07K005/00 ,  C07K007/00 ,  C07K016/00 ,  C07K017/00 ,  A61K038/12

CPC classification number: C07K7/64 ,  A61K38/00 ,  C07B59/008 ,  C07K1/13 ,  C07K7/645 ,  Y10S530/806 ,  Y10S530/807

Abstract: Cyclosporine derivatives are disclosed which possess enhanced efficacy and reduced toxicity over naturally occurring and other presently known cyclosporins and cyclosporine derivatives. The cyclosporine derivatives of the present invention are produced by chemical and isotopic substitution of the cyclosporine A (CsA) molecule by: (1) Chemical substitution and optionally deuterium substitution of amino acid 1; and (2) deuterium substitution at key sites of metabolism of the cyclosporine A molecule such as amino acids 1, 4, 9. Also disclosed are methods of producing the cyclosporine derivatives and method of producing immunosuppression with reduced toxicity with the disclosed cyclosporine derivatives.

Abstract translation: 公开了与天然存在的和其他目前已知的环孢菌素和环孢菌素衍生物相比具有增强的功效和降低的毒性的环孢菌素衍生物。 本发明的环孢菌素衍生物通过以下方式通过环孢菌素A（CsA）分子的化学和同位素取代产生：（1）氨基酸1的化学取代和任选的氘取代; 和（2）在环孢菌素A分子的代谢关键位置的氘代替，例如氨基酸1,4,9。还公开了产生环孢菌素衍生物的方法和与所公开的环孢菌素衍生物一起产生具有降低的毒性的免疫抑制的方法。